Literature DB >> 33431223

Infant immunity against viral infections is advanced by the placenta-dependent vertical transfer of maternal antibodies.

Marie Albrecht1, Mirja Pagenkemper2, Christian Wiessner3, Michael Spohn4, Marc Lütgehetmann5, Henning Jacobsen6, Gülsah Gabriel7, Dimitra E Zazara8, Christoph Haertel9, Kurt Hecher2, Anke Diemert2, Petra Clara Arck10.   

Abstract

Neonatal passive immunity, derived from transplacental transfer of IgG antibodies from mother to fetus during pregnancy, can mitigate the risk for severe infections in the early postnatal period. Understanding the placenta as the gateway organ in this process, we aimed to evaluate the influence of specific factors modulating the transplacental IgG transfer rate (TPTR) in 141 mother/neonate pairs. We further evaluated the potential health advantage elicited by maternal IgG with regard to respiratory tract infections during infancy and early childhood. Data and biological samples collected within the prospective longitudinal pregnancy cohort study PRINCE (Prenatal Identification of Children's Health) were used for these analyses. We tested IgG antibody levels against seven pathogens (measles, mumps, rubella, tetanus, diphtheria, pertussis and influenza A) by ELISA and detected seropositivity in 72.6-100% of pregnant women and in 76.3-100% of their neonates, respectively. Cord blood IgG levels reached 137-160% of levels detected in maternal blood. Strikingly, assessment of TPTR for all seven antigens highlighted that TPTR strongly depends on individual placental function. Subsequent in-depth analysis of anti-influenza A IgG revealed a link between cord blood levels and uterine perfusion, measured by uterine artery pulsatility index. Moreover, higher cord blood anti-influenza A IgG levels were associated with a significantly reduced risk for respiratory tract infections during the first six months of life, indicating a high degree of cross-reactivity and possible pathogen-agnostic effects of anti-influenza A antibodies. Taken together, our data suggest that early life immunity is modulated by maternal IgG levels and individual placental features such as perfusion. Vaccination of pregnant women, i.e. against influenza, can increase neonatal antibody levels and hereby protect against early life respiratory infections. Consequently, specific guidelines should evolve in order to safeguard neonates born from pregnancies with poorer placental capacity for vertical transfer of protective antibodies.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Maternal vaccination; Neonatal immunity; Pregnancy cohort; Transplacental antibody transfer; Ultrasound; Vaccine-preventable diseases

Mesh:

Substances:

Year:  2021        PMID: 33431223     DOI: 10.1016/j.vaccine.2020.12.049

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

Review 1.  Establishment of tissue-resident immune populations in the fetus.

Authors:  Dorien Feyaerts; Christopher Urbschat; Brice Gaudillière; Ina A Stelzer
Journal:  Semin Immunopathol       Date:  2022-05-04       Impact factor: 11.759

2.  Placental Injury and Antibody Transfer Following COVID-19 Disease in Pregnancy.

Authors:  Patience Timi; Sarah E Kellerhals; Naima T Joseph; Carolynn M Dude; Hans P Verkerke; Les'Shon S Irby; Alicia K Smith; Sean R Stowell; Denise J Jamieson; Martina L Badell
Journal:  J Infect Dis       Date:  2022-06-29       Impact factor: 7.759

3.  Racial concentration and dynamics of COVID-19 vaccination in the United States.

Authors:  Cary Wu
Journal:  SSM Popul Health       Date:  2022-08-18

4.  Inefficient Placental Virus Replication and Absence of Neonatal Cell-Specific Immunity Upon Sars-CoV-2 Infection During Pregnancy.

Authors:  Ann-Christin Tallarek; Christopher Urbschat; Luis Fonseca Brito; Stephanie Stanelle-Bertram; Susanne Krasemann; Giada Frascaroli; Kristin Thiele; Agnes Wieczorek; Nadine Felber; Marc Lütgehetmann; Udo R Markert; Kurt Hecher; Wolfram Brune; Felix Stahl; Gülsah Gabriel; Anke Diemert; Petra Clara Arck
Journal:  Front Immunol       Date:  2021-06-03       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.